Inhibitory effect of Endostar on HIF-1 with upregulation of MHC-I in lung cancer cells
Endostar is a human recombinant endostatin which is an attractive anti-angiogenesis protein. Because inefficient antigen presenting MHC class I expression (which can be downregulated by HIF-1) is an important strategy for cancer immune evasion, besides its anti-angiogenesis effect, it remains unclea...
Saved in:
| Main Authors: | Ming-Zhen Zhao, Hong-Fei Zheng, Jing-Na Wang, Yan-Min Zhang, Hai-Jing Wang, Zhi-Wei Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2025.2508535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP‐Endostar Combination Therapy
by: Min Zhang, et al.
Published: (2025-06-01) -
The safety of combining Endostar with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer and the evaluation of its anti-angiogenic effects via transrectal contrast-enhanced ultrasound
by: Fang Wu, et al.
Published: (2025-05-01) -
MHC-I pathway disruption by viruses: insights into immune evasion and vaccine design for animals
by: Yanan Wu, et al.
Published: (2025-05-01) -
OnmiMHC: a machine learning solution for UCEC tumor vaccine development through enhanced peptide-MHC binding prediction
by: Fangfang Jian, et al.
Published: (2025-02-01) -
Editorial: Specific targeting of MHC antigens for T-cells and immune cells in human disease
by: Ali Afzal, et al.
Published: (2025-01-01)